OneMedNet Inks Multi-Year Resale Deal with Atropos Health, Adding Recurring Revenue
ONMD sits 39% above its 52-week low of $0.49 on light trading volume (0.3× avg).
Summary
OneMedNet signed a 3-year subscription-based license with Atropos Health, embedding its regulatory-grade real-world data into Atropos' evidence-generation platform. The deal adds to OneMedNet's annual recurring revenue, though no dollar value was disclosed. This follows a July agreement worth over $11.5 million for AI model training data, showing continued commercial traction. The partnership expands distribution to Atropos' health system and life sciences customers, potentially accelerating revenue growth. Watch for revenue contribution details in upcoming quarterly filings.
At the time of this announcement, ONMD was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $0.49 to $4.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.